Published in Int J Cancer on January 01, 2000
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
Molecular profiling of breast cancer: clinical implications. Br J Cancer (2004) 1.19
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol (2012) 1.09
Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer (2001) 1.07
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res (2003) 0.99
Heterogeneity of mammary lesions represent molecular differences. BMC Cancer (2006) 0.98
Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer (2010) 0.91
Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer (2012) 0.90
Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol (2012) 0.84
The interrelationship between DRIM gene expression and cytogenetic and phenotypic characteristics in human breast tumor cell lines. BMC Genomics (2003) 0.83
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer? Int J Surg Oncol (2012) 0.80
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. Oncotarget (2016) 0.75
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. Breast Cancer Res (2015) 0.75
Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol (2016) 0.75
Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer (1999) 6.86
Orbital and millennial Antarctic climate variability over the past 800,000 years. Science (2007) 5.10
The leader peptide of yeast gene CPA1 is essential for the translational repression of its expression. Cell (1987) 4.91
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res (1994) 4.51
Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol (2001) 4.18
Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet (1995) 3.12
Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05
A clinical pathway to accelerate recovery after colonic resection. Ann Surg (2000) 3.04
Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg (2000) 2.85
Mutations of the human E-cadherin (CDH1) gene. Hum Mutat (1998) 2.84
Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol (2006) 2.84
Heterogeneity in breast cancer and the problem of relevance of findings. Anal Cell Pathol (1999) 2.81
The structure of coxsackievirus B3 at 3.5 A resolution. Structure (1995) 2.73
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut (2003) 2.49
Inactivation of the protein phosphatase 2A regulatory subunit A results in morphological and transcriptional defects in Saccharomyces cerevisiae. Mol Cell Biol (1992) 2.33
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Ethical problems in medical practice. A protocol for the guidance of physicians. West J Med (1982) 2.19
A protein-protein interaction map of yeast RNA polymerase III. Proc Natl Acad Sci U S A (1999) 2.18
Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol (1997) 2.16
Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci (1982) 2.14
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
The Gorham-Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings. J Bone Joint Surg Br (1999) 2.07
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
A collagen disorder of the nervous system presenting as multiple sclerosis. Brain (1972) 2.00
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch (1995) 1.91
Suppression of yeast RNA polymerase III mutations by FHL1, a gene coding for a fork head protein involved in rRNA processing. Mol Cell Biol (1994) 1.91
Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene (1995) 1.81
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol (1998) 1.79
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg (1996) 1.69
The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A (1999) 1.69
Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. Hum Mol Genet (1996) 1.65
From first base: the sequence of the tip of the X chromosome of Drosophila melanogaster, a comparison of two sequencing strategies. Genome Res (2001) 1.64
Effect of histamine H2-receptor blockade on vagally induced gastric secretion in man. Br Med J (1974) 1.63
Epidemiology of single and multiple species of helminth infections among school children in Busia District, Kenya. East Afr Med J (2000) 1.62
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol (1999) 1.61
Connexin43 null mice reveal that astrocytes express multiple connexins. Brain Res Brain Res Rev (2000) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol (2007) 1.60
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet (1999) 1.59
Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol (2006) 1.58
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Serum protein changes during the acute phase reaction. Clin Chim Acta (1969) 1.57
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report. Antimicrob Agents Chemother (1992) 1.57
Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene (1999) 1.55
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 1.52
Anaerobic pericarditis: case report and review. Clin Infect Dis (1994) 1.52
Early diagnosis and prevention of sporadic colorectal cancer. Endoscopy (2001) 1.51
Dual role of the C34 subunit of RNA polymerase III in transcription initiation. EMBO J (1997) 1.51
Single-cell mutation analysis of tumors from stained histologic slides. Lab Invest (1996) 1.49
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity (2002) 1.49
Detection of small RB1 gene deletions in retinoblastoma by multiplex PCR and high-resolution gel electrophoresis. Hum Genet (1992) 1.49
The nature of giant cell tumor of bone. J Cancer Res Clin Oncol (2001) 1.47
A universally conserved region of the largest subunit participates in the active site of RNA polymerase III. EMBO J (1995) 1.45
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer (2007) 1.45
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia (2000) 1.45
The yeast RNA polymerase III transcription machinery: a paradigm for eukaryotic gene activation. Cold Spring Harb Symp Quant Biol (1998) 1.45
Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ (2001) 1.44
[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. Chirurg (2008) 1.44
What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer (1997) 1.43
A segment of mRNA encoding the leader peptide of the CPA1 gene confers repression by arginine on a heterologous yeast gene transcript. Mol Cell Biol (1994) 1.43
Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet (1995) 1.42
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer (2008) 1.42
[Participation and support of clinical studies and other scientific investigations. Statement of the German Society for Pathology]. Pathologe (2013) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg (2000) 1.41
Detection of somatic changes in human renal cell carcinomas with oligonucleotide probes specific for simple repeat motifs. Genes Chromosomes Cancer (1993) 1.40
The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia (2006) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Molecular diagnosis of a Mycobacterium chelonae infection. Pathol Res Pract (2001) 1.39
[Thoracic pain in a power athlete]. Internist (Berl) (1997) 1.39
Heterotopic pancreatitis with obstruction of the major duodenal papill--a rare trigger of obstructive orthotopic pancreatitis. Pancreatology (2004) 1.39
Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet (2004) 1.38
A mutation in the C31 subunit of Saccharomyces cerevisiae RNA polymerase III affects transcription initiation. EMBO J (1995) 1.38
Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis (2002) 1.38
Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med (1999) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol (2011) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ. Differentiation (1986) 1.32
Immunoscintigraphy of colon carcinoma. J Nucl Med (1984) 1.31